FDA emphasises need for adverse event reporting of compounded drugs
The FDA says that even though it recognises the importance of compounded drugs, they also pose a risk to patient safety.
List view / Grid view
The FDA says that even though it recognises the importance of compounded drugs, they also pose a risk to patient safety.
GVOKE injection has received regulatory approval from the FDA for the treatment of severe hypoglycemia in patients with diabetes.
An import of medicinal cannabis from Portugal to Germany signifies the largest quantity ever moved within the EU, highlighting a surge in the medicinal cannabis products market.
The seven centres will aid disease research and clinical development, improving access to patient data for studies.
A settlement has purportedly been agreed between Purdue Pharma and 23 US states to resolve the opioid crisis case against the company.
According to a new report, blockchain technology in the healthcare market size is set to increase exponentially.
The Operation Yellowhammer document has been published, which states that the UK will experience severe delays to the medical supply chain following a no-deal Brexit.
Orphan Drug Designation has been given to sotatercept for the treatment of patients with pulmonary arterial hypertension.
Tepotinib, an investigational therapy for patients with metastatic non-small cell lung cancer has been given Breakthrough Therapy Designation.
The lobbying group Innovative Medicines Canada has announced its lawsuit against plans to lower drug prices in the country.
Bacteriostatic Water is being recalled because of a lack of sterilisation confirmation for some vials.
Research has found that the worldwide LC-MS market will be worth $2750 million by the end of the forecast period in 2024.
The Kymriah (tisagenlecleucel) treatment has received a positive appraisal from the Scottish Medicines Consortium, after EMA approval last year.
Novartis reportedly knew of discrepancies in the Zolgensma data it had submitted to the FDA but delayed informing regulators so has announced alterations to its processes.
Both the intravenous and oral formulations of the antifungal candidate, fosmanogepix, have been granted Fast Track designation by the FDA.